Related Experiment Videos
Antibodies to interferon alpha in patients
1Department of Biomedicine, University of Pisa, Italy.
Archives of Virology. Supplementum
|January 1, 1993
Summary
Interferons (IFNs) are effective antiviral and anticancer agents. However, some patients develop anti-IFN antibodies, potentially impacting treatment efficacy. This review summarizes current knowledge on these antibodies.
Area of Science:
- Immunology
- Virology
- Oncology
Background:
- Interferons (IFNs) were first described as antiviral agents in 1957.
- Human IFNs have been clinically utilized for over a decade, demonstrating efficacy in treating certain cancers and viral infections.
- A notable observation during IFN therapy is the potential development of anti-IFN antibodies in patients.
Purpose of the Study:
- To review the biological and clinical significance of antibodies developed against interferons during therapeutic use.
- To consolidate current understanding of anti-IFN antibody formation and its implications.
Main Methods:
- Literature review of studies on interferon therapy and associated antibody development.
- Synthesis of existing data on the biological characteristics and clinical impact of anti-IFN antibodies.
Main Results:
- Development of antibodies to interferons can occur in patients undergoing IFN treatment.
- These anti-IFN antibodies have the potential to influence the therapeutic effectiveness of interferon treatments.
- Understanding the mechanisms and consequences of antibody formation is crucial for optimizing IFN therapy.
Conclusions:
- Anti-IFN antibodies represent a significant factor affecting the clinical efficacy of interferon treatments.
- Further research into the biological and clinical aspects of anti-IFN antibodies is warranted.
- Managing or mitigating the effects of anti-IFN antibodies may improve patient outcomes in IFN therapy.